Confluent stock (CFLT) drops as IBM deal vote approaches and SEC filing raises concerns about shareholder lawsuits
Confluent, a data-streaming software company, saw a slight decline in its shares by 0.4% on Wednesday, closing the day at $30.33. This drop comes as the company increases disclosures regarding its impending acquisition by IBM, amidst ongoing shareholder lawsuits. Despite IBM’s $31-per-share cash bid, Confluent’s stock price continues to fall just below this mark.
At the forefront of investors’ minds now are the upcoming events surrounding the deal. With a shareholder vote scheduled for next week and Confluent’s imminent earnings report after the markets close on February 11, market watchers are closely monitoring how these factors will impact the acquisition.
Investors are also keeping a close eye on the spread between Confluent’s current stock price and IBM’s offer price to gauge the deal’s stability. A wider spread typically indicates market concerns about potential delays or complications that could jeopardize the acquisition.
In a recent SEC filing on February 4, Confluent revealed that it had received 17 demand letters and is facing two lawsuits in New York alleging inaccuracies or omissions in its merger proxy. While the company has denied any wrongdoing, it has agreed to provide additional disclosures to address these concerns. These updates will include more information on Morgan Stanley’s valuation analysis and reference similar transactions in the industry.
IBM views the acquisition of Confluent as a strategic move to bolster its AI-focused data infrastructure for enterprise software. IBM CEO Arvind Krishna highlighted the importance of the deal, stating that it will position IBM as a leader in providing smart data platforms for AI-driven applications.
As the path to closing the deal progresses, Confluent is preparing for a special shareholder meeting on February 12 to vote on the adoption of the merger agreement. With the stock trading at a slight discount to IBM’s offer price, investors are cautiously optimistic about the deal’s completion. However, uncertainties surrounding timing, regulatory approvals, and potential litigation remain key risks.
With Confluent set to release its fourth-quarter and full-year 2025 results after the market closes on February 11, investors are eagerly anticipating any additional updates or disclosures that could impact the deal outcome. As the company navigates these challenges in the lead-up to the shareholder vote, the market awaits further clarity on the fate of this high-profile acquisition.